Please ensure Javascript is enabled for purposes of website accessibility

Why Altimmune Stock Is Jumping Today

By Keith Speights – Sep 25, 2020 at 11:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst's buy recommendation fueled investors' enthusiasm about the biotech stock.

What happened

Shares of Altimmune (ALT 8.84%) were jumping 12.2% higher as of 10:58 a.m. EDT on Friday. The big gain came after B. Riley FBR analyst Chad Mabry initiated coverage on the stock with a buy recommendation.

So what

It's important to keep in mind that analysts' buy recommendations change nothing about the underlying prospects for a company. They simply mean that a given analyst is recognizing those prospects. And the analyst's view could be completely on target or dead wrong.

One hand with a thumb up and the other hand holding cash fanned out

Image source: Getty Images.

With biotech stocks such as Altimmune, evaluating whether or not analysts are more likely to be right or not is difficult. Altimmune doesn't have any products on the market yet. The company's lead pipeline candidate, intranasal flu vaccine Nasovax, is only in phase 2 testing. There isn't a lot of clinical data to go on to assess the biotech's chances of success at this point.

However, there are some reasons to be cautiously optimistic about Altimmune's prospects. The company's pipeline includes four clinical-stage programs with two other early-stage studies planned to begin later this year. Results from preclinical and clinical testing conducted so far for these candidates have been encouraging.

Altimmune also lined up federal funding for its anthrax intranasal vaccine and T-COVID intranasal coronavirus vaccine programs. This external funding is a positive sign about the potential for these vaccines.

Now what

The main thing for investors to watch with Altimmune is its pipeline progress. Altimmune plans to initiate a phase 1 study of its AdCOVID coronavirus vaccine in the fourth quarter of 2020. It expects to begin a multinational phase 2 trial evaluating HepTcell in treating chronic hepatitis B before year-end. In addition, the biotech anticipates reporting results from a phase 1 study of ALT-801 in treating nonalcoholic steatohepatitis (NASH) next spring. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

$10.83 (8.84%) $0.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.